Dr. Joseph John Memminger Iii, MDPH.D Pathology - Clinical Pathology/Laboratory Medicine Medicare: Not Enrolled in Medicare Practice Location: 23885 Denton St Ste B, Clinton Township, MI 48036 Phone: 941-914-4321 |
Dr. Daniel Joseph Spitz, M.D. Pathology - Forensic Pathology Medicare: Not Enrolled in Medicare Practice Location: 34051 S Gratiot Ave, Suite 202, Clinton Township, MI 48035 Phone: 586-791-6700 |
George O Kucy, MD Pathology - Anatomic Pathology & Clinical Pathology Medicare: Accepting Medicare Assignments Practice Location: 15855 19 Mile Rd, Clinton Township, MI 48038 Phone: 586-263-2458 Fax: 586-263-2258 |
Demetrius Govan, Pathology - Medical Microbiology Medicare: Not Enrolled in Medicare Practice Location: 20575 Harmony Dr, Clinton Township, MI 48036 Phone: 313-721-2413 |
Dr. Mary Beth Anderson, D.O. Pathology - Dermatopathology Medicare: Medicare Enrolled Practice Location: 18756 Millar Rd, Clinton Township, MI 48036 Phone: 586-381-0177 Fax: 859-987-7661 |
Eve M Vanegmond, MD Pathology - Anatomic Pathology & Clinical Pathology Medicare: Not Enrolled in Medicare Practice Location: 15855 19 Mile Rd, Clinton Township, MI 48038 Phone: 586-263-2461 |
Dr. Wendy Frauchiger, MD Pathology - Clinical Pathology/Laboratory Medicine Medicare: Accepting Medicare Assignments Practice Location: 15855 19 Mile Rd, Clinton Township, MI 48038 Phone: 586-872-8121 |
News Archive
Research led by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) has shown that therapeutic cloning, also known as somatic-cell nuclear transfer (SCNT), can be used to treat Parkinson's disease in mice.
BD Diagnostics, a segment of BD, a leading global medical technology company, today introduced two new erythrocyte sedimentation rate instruments in Europe that standardise analysis for more accurate, timely results and an efficient workflow in comparison to a manual Westergren method. This next generation of BD ESR instruments results in improved patient care in the laboratory or point of care setting.
Abeona Therapeutics, a start-up company created around intellectual property licensed from Nationwide Children's Hospital to develop treatments for Sanfilippo Syndrome Types A and B, has been granted Orphan Drug Designations for its lead investigational therapies by the U.S. Food and Drug Administration Office of Orphan Products Development.
Delcath Systems, Inc., a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that results of a large, European single-center experience of the treatment of uveal melanoma patients with hepatic metastases with the Delcath Hepatic CHEMOSAT® Delivery System, were highlighted in an on-line abstract at the American Society of Clinical Oncology Annual Meeting 2015.
› Verified 6 days ago